|
|
Line 3: |
Line 3: |
| <StructureSection load='5kax' size='340' side='right'caption='[[5kax]], [[Resolution|resolution]] 2.00Å' scene=''> | | <StructureSection load='5kax' size='340' side='right'caption='[[5kax]], [[Resolution|resolution]] 2.00Å' scene=''> |
| == Structural highlights == | | == Structural highlights == |
- | <table><tr><td colspan='2'>[[5kax]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Chlte Chlte]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5KAX OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5KAX FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[5kax]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Chlorobaculum_tepidum_TLS Chlorobaculum tepidum TLS]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5KAX OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5KAX FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=RHQ:RHODAMINE+6G'>RHQ</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2Å</td></tr> |
- | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">CT0179 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=194439 CHLTE])</td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=RHQ:RHODAMINE+6G'>RHQ</scene></td></tr> |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5kax FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5kax OCA], [http://pdbe.org/5kax PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5kax RCSB], [http://www.ebi.ac.uk/pdbsum/5kax PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5kax ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5kax FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5kax OCA], [https://pdbe.org/5kax PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5kax RCSB], [https://www.ebi.ac.uk/pdbsum/5kax PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5kax ProSAT]</span></td></tr> |
| </table> | | </table> |
| + | == Function == |
| + | [https://www.uniprot.org/uniprot/Q8KFZ1_CHLTE Q8KFZ1_CHLTE] |
| <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
Line 21: |
Line 23: |
| __TOC__ | | __TOC__ |
| </StructureSection> | | </StructureSection> |
- | [[Category: Chlte]] | + | [[Category: Chlorobaculum tepidum TLS]] |
| [[Category: Large Structures]] | | [[Category: Large Structures]] |
- | [[Category: Moreno, A]] | + | [[Category: Moreno A]] |
- | [[Category: Wade, H]] | + | [[Category: Wade H]] |
- | [[Category: Gyri-like domatin]]
| + | |
- | [[Category: Multi-drug recognition]]
| + | |
- | [[Category: Unknown function]]
| + | |
| Structural highlights
Function
Q8KFZ1_CHLTE
Publication Abstract from PubMed
Multidrug resistance (MDR) refers to the acquired ability of cells to tolerate a broad range of toxic compounds. One mechanism cells employ is to increase the level of expression of efflux pumps for the expulsion of xenobiotics. A key feature uniting efflux-related mechanisms is multidrug (MD) recognition, either by efflux pumps themselves or by their transcriptional regulators. However, models describing MD binding by MDR effectors are incomplete, underscoring the importance of studies focused on the recognition elements and key motifs that dictate polyspecific binding. One such motif is the GyrI-like domain, which is found in several MDR proteins and is postulated to have been adapted for small-molecule binding and signaling. Here we report the solution binding properties and crystal structures of two proteins containing GyrI-like domains, SAV2435 and CTR107, bound to various ligands. Furthermore, we provide a comparison with deposited crystal structures of GyrI-like proteins, revealing key features of GyrI-like domains that not only support polyspecific binding but also are conserved among GyrI-like domains. Together, our studies suggest that GyrI-like domains perform evolutionarily conserved functions connected to multidrug binding and highlight the utility of these types of studies for elucidating mechanisms of MDR.
Solution Binding and Structural Analyses Reveal Potential Multidrug Resistance Functions for SAV2435 and CTR107 and Other GyrI-like Proteins.,Moreno A, Froehlig JR, Bachas S, Gunio D, Alexander T, Vanya A, Wade H Biochemistry. 2016 Aug 30;55(34):4850-63. doi: 10.1021/acs.biochem.6b00651. Epub , 2016 Aug 18. PMID:27505298[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Moreno A, Froehlig JR, Bachas S, Gunio D, Alexander T, Vanya A, Wade H. Solution Binding and Structural Analyses Reveal Potential Multidrug Resistance Functions for SAV2435 and CTR107 and Other GyrI-like Proteins. Biochemistry. 2016 Aug 30;55(34):4850-63. doi: 10.1021/acs.biochem.6b00651. Epub , 2016 Aug 18. PMID:27505298 doi:http://dx.doi.org/10.1021/acs.biochem.6b00651
|